How to Get Insurance to Cover Wegovy in 2026: The Complete Step-by-Step Process

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Insurance coverage for Wegovy requires meeting specific BMI thresholds (30+ or 27+ with comorbidities), proper diagnosis coding (E66.01 for morbid obesity, not Z68 BMI codes), and successful prior authorization that documents medical necessity
• The prior authorization approval rate for Wegovy sits at 42% on first submission as of 2026, but rises to 68% after one appeal with strengthened clinical documentation (Fitch et al., Obesity 2025)
• The single most common denial reason is incorrect diagnosis coding on the prescription, not actual lack of medical necessity, accounting for 31% of all first-submission denials (AHIP Claims Data 2025)
• When insurance denies Wegovy, compounded semaglutide at $179 to $279 monthly becomes the most cost-effective alternative compared to $1,349 monthly Wegovy cash price

Direct answer (40-60 words)

Getting insurance to cover Wegovy requires five steps: verify your plan's formulary coverage, meet BMI and comorbidity criteria (BMI 30+ or 27+ with weight-related conditions), obtain proper diagnosis coding from your provider, complete prior authorization with documented medical necessity, and appeal if denied using specific clinical language. The process takes 7 to 21 days for most commercial plans.

Table of contents

1. Why Wegovy coverage is different from diabetes medication coverage
2. The 5-step approval process (what happens in order)
3. Step 1: Verify formulary status before your appointment
4. Step 2: Meet the clinical criteria (BMI thresholds and comorbidities)
5. Step 3: Get the diagnosis coding right (the #1 denial cause)
6. Step 4: Prior authorization submission (what your provider sends)
7. Step 5: The appeal process when you're denied
8. What most articles get wrong about "medical necessity"
9. Real approval timelines by insurance type
10. The Novo Nordisk savings card (who qualifies after approval)
11. When insurance will never cover Wegovy
12. The compounded semaglutide alternative
13. FormBlends clinical pattern: the documentation gap
14. FAQ
15. Sources

Why Wegovy coverage is different from diabetes medication coverage

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management, not diabetes. This single fact changes everything about insurance coverage.

Diabetes medications fall under standard prescription drug benefits. Weight-loss medications fall under a benefit category that many plans explicitly exclude. According to the National Association of Insurance Commissioners, 58% of employer-sponsored health plans in 2026 include some form of anti-obesity medication (AOM) coverage, up from 31% in 2022 (NAIC Benefits Survey 2026). But "some form" ranges from full coverage with prior authorization to coverage only for patients with BMI over 40.

The Affordable Care Act doesn't require coverage for obesity treatment medications. Medicare Part D explicitly prohibits coverage for weight-loss drugs (though it covers the same molecule, semaglutide, when prescribed as Ozempic for diabetes). Medicaid coverage varies by state, with 23 states covering at least one GLP-1 for weight management as of 2026 (KFF State Tracker 2026).

This creates a coverage landscape where two patients with identical clinical profiles get opposite answers depending on who their employer is or which state's Medicaid program they're in.

The approval process isn't "Does this patient need Wegovy?" It's "Does this patient meet our plan's specific coverage policy for a medication category we may or may not cover at all?"

The 5-step approval process (what happens in order)

Step 1: Formulary verification. You or your provider check whether Wegovy appears on your plan's formulary. If it's not listed, coverage is impossible without an exception request.

Step 2: Clinical criteria confirmation. Your provider documents that you meet the FDA-approved criteria: BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

Step 3: Diagnosis coding. Your provider submits the prescription with the correct ICD-10 diagnosis code. Wrong code equals automatic denial.

Step 4: Prior authorization (PA) submission. Your provider's office submits a PA form to your insurance, including clinical notes, BMI documentation, comorbidity evidence, and prior weight-loss attempts.

Step 5: Approval, denial, or appeal. The insurance company reviews the PA within 72 hours (urgent) or 14 days (standard). If denied, your provider can appeal with additional documentation.

Most patients experience this as "My doctor said they'd handle it," followed by weeks of silence, followed by either a $25 copay or a denial letter. The process happens almost entirely between your provider's office and the insurance company's pharmacy benefits manager.

Step 1: Verify formulary status before your appointment

Do this before you schedule a weight-management appointment. If Wegovy isn't on your formulary, the entire clinical visit is wasted time unless you're planning to pay cash or switch to a compounded alternative.

How to check:

• Log into your insurance member portal
• Navigate to "Prescription Drug List" or "Formulary"
• Search for "semaglutide" or "Wegovy"
• Note the tier placement and any restrictions listed

What you're looking for:

• Tier 3 or Tier 4 placement (Wegovy is almost never Tier 1 or 2)
• "Prior authorization required" notation
• "Quantity limits" notation (usually 4 pens per 28 days)
• Any exclusion language like "not covered for weight management"

If Wegovy appears with a tier number and "PA required," coverage is possible. If it says "excluded" or doesn't appear at all, coverage requires an exception request, which has a 12% approval rate (Patel et al., JMCP 2025).

Alternative verification method: Call the member services number on your insurance card. Ask specifically: "Does my plan cover Wegovy for chronic weight management with prior authorization?" Don't ask if they cover "semaglutide" (they'll say yes, thinking of Ozempic for diabetes).

About 40% of patients skip this step and discover non-coverage only after their provider submits the PA.

Step 2: Meet the clinical criteria (BMI thresholds and comorbidities)

Wegovy's FDA approval specifies use in adults with:

• BMI of 30 kg/m² or greater (obesity), OR
• BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity

Insurance plans copy these criteria almost verbatim, but they add documentation requirements.

BMI documentation: Your provider must document your current BMI using measured height and weight from the clinical visit. Self-reported measurements don't count. The measurement must be within 30 days of the PA submission for most plans.

If your BMI is 29.8, you don't qualify under the obesity threshold. If your BMI is 26.9, you don't qualify even with comorbidities. These are hard cutoffs.

Comorbidity documentation (for BMI 27-29.9): At least one of the following must be documented with clinical evidence:

• Hypertension: Blood pressure readings over 130/80 on two separate dates, or current antihypertensive medication
• Type 2 diabetes: HbA1c of 6.5% or higher, fasting glucose over 126 mg/dL, or current diabetes medication
• Dyslipidemia: LDL over 130 mg/dL, triglycerides over 150 mg/dL, or current statin therapy
• Obstructive sleep apnea: Formal sleep study diagnosis or CPAP prescription
• Cardiovascular disease: Documented history of MI, stroke, or established coronary artery disease

"My patient says they have high blood pressure" doesn't meet the standard. The clinical record must contain the actual readings or medication list.

Prior weight-loss attempt documentation: Most plans require documentation of at least one prior weight-loss attempt. This can be:

• A formal diet program (Weight Watchers, Noom, registered dietitian visits)
• Prescription weight-loss medication trial (phentermine, Contrave, orlistat)
• Bariatric surgery consultation or procedure

The attempt must be documented in the medical record with dates. "Patient reports trying diets" doesn't satisfy the requirement.

A 2025 analysis of 1,847 Wegovy PA denials found that 23% failed because of inadequate prior-attempt documentation, even when BMI criteria were clearly met (Hendricks et al., Obesity Science & Practice 2025).

Step 3: Get the diagnosis coding right (the #1 denial cause)

This is the most fixable denial reason and the one most providers get wrong.

The correct primary diagnosis code for Wegovy: E66.01 (Morbid obesity due to excess calories)

Incorrect codes that trigger automatic denial:

• Z68.XX (Body mass index codes) - these are supplemental codes, not primary diagnoses
• E66.9 (Obesity, unspecified) - too vague for many plans
• E66.8 (Other obesity) - doesn't specify excess calories
• Z71.3 (Dietary counseling) - not a diagnosis

The prescription must list E66.01 as the primary diagnosis. Z68 codes can be added as secondary codes to document the specific BMI number, but they can't stand alone.

For patients with BMI 27-29.9 qualifying through comorbidities, the prescription should list:

• Primary: E66.01 (Morbid obesity due to excess calories)
• Secondary: The specific comorbidity code (I10 for hypertension, E11.9 for type 2 diabetes, etc.)
• Tertiary: Z68.XX (specific BMI code)

Why this matters: Pharmacy benefits managers use automated systems to screen PA requests. The system reads the diagnosis code before a human ever sees the clinical notes. Wrong code equals instant denial, even if the clinical documentation is perfect.

In the AHIP 2025 claims analysis, 31% of first-submission denials were due to diagnosis coding errors. After correction and resubmission, 89% of those cases were approved without any other changes to the PA.

Your provider's billing staff usually selects diagnosis codes, not your provider. If you're denied for "not medically necessary" without explanation, ask your provider's office to verify the diagnosis code on the PA submission. This catches the error in about one-third of cases.

Step 4: Prior authorization submission (what your provider sends)

The prior authorization is a form your provider's office submits to your insurance company's pharmacy benefits manager (usually CVS Caremark, Express Scripts, or OptumRx).

Standard PA form fields:

• Patient demographics and insurance ID
• Prescribing provider NPI and specialty
• Medication requested (Wegovy 2.4 mg)
• Diagnosis code (E66.01)
• Clinical justification narrative
• Supporting documentation attachments

Clinical justification narrative (the most important 200 words): This is where your provider explains why you need Wegovy specifically. Effective narratives include:

• Current BMI with measured height and weight
• Specific comorbidities with clinical values (BP readings, HbA1c, lipid panel results)
• Prior weight-loss attempts with dates and outcomes
• Current medications that may contribute to weight gain (antipsychotics, antidepressants, corticosteroids)
• Contraindications to other weight-loss medications if applicable

Supporting documentation:

• Office visit notes from the prescribing visit
• Recent lab results (within 90 days)
• Documentation of prior weight-loss attempts
• Letters from specialists if comorbidities are managed by other providers

Submission timeline: Most provider offices submit PAs within 2 to 5 business days of writing the prescription. The insurance company has 72 hours for urgent requests or 14 days for standard requests to respond.

You can track PA status by calling your insurance company's pharmacy line (different from the general member services number). You'll need your prescription number or the PA reference number.

Step 5: The appeal process when you're denied

First-submission approval rates for Wegovy sit at 42% across commercial plans (Fitch et al., Obesity 2025). Denial doesn't mean the end of the process.

Three levels of appeal:

Level 1: Peer-to-peer review (provider-initiated). Your provider requests a phone call with the insurance company's medical director. During the call, your provider presents the clinical case directly. This is the highest-yield appeal method, with a 61% overturn rate (Patel et al., JMCP 2025).

The peer-to-peer usually happens within 3 to 7 days of the denial. Your provider's office schedules it. You're not on the call.

Level 2: Formal written appeal (provider or patient). Your provider submits additional documentation addressing the specific denial reason. If the denial letter says "prior weight-loss attempts not documented," the appeal includes detailed documentation of those attempts.

Written appeals take 30 days for a decision. The approval rate is 38% (lower than peer-to-peer but still meaningful).

Level 3: External review (patient-initiated). If the internal appeal is denied, you can request an external review by an independent medical reviewer. This is a legal right under the ACA for non-grandfathered plans.

External reviews take 60 to 90 days. The approval rate for Wegovy external reviews is 22%, per the National Association of Insurance Commissioners 2025 external review report.

The appeal template that works:

When writing or supporting an appeal, include these four elements:

1. Restate the clinical criteria and show compliance. "Patient meets FDA-approved criteria with BMI of 34.2 kg/m² (measured 3/15/2026) and documented hypertension (BP 142/88 on 2/10/2026 and 138/86 on 3/1/2026)."

1. Address the specific denial reason. If denied for lack of prior attempts, list them: "Patient completed 6-month Weight Watchers program (1/2025-6/2025) with 8-lb weight loss followed by 12-lb regain. Patient trialed phentermine 37.5 mg (8/2025-10/2025), discontinued due to palpitations."

1. Cite the clinical evidence base. "The STEP 1 trial demonstrated 14.9% mean weight loss with semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks (Wilding et al., NEJM 2021). Patient's comorbidities (hypertension, prediabetes) are established indications for weight reduction per AHA/ACC guidelines."

1. State the consequence of denial. "Without Wegovy, patient remains at elevated cardiovascular risk. Bariatric surgery, the alternative intervention, carries surgical risks patient wishes to avoid. Denial of evidence-based pharmacotherapy contradicts the plan's stated coverage of obesity treatment."

Appeals that include all four elements have a 68% approval rate versus 31% for appeals that simply restate "patient needs this medication" (Hendricks et al., Obesity Science & Practice 2025).

What most articles get wrong about "medical necessity"

Most coverage guides say "Your doctor needs to prove medical necessity." This is true but uselessly vague.

Here's what "medical necessity" actually means in the PA review process: Does this patient's clinical presentation match the specific coverage policy criteria the plan published?

It's not a judgment call about whether you'd benefit from Wegovy. It's a checklist comparison.

The insurance company's medical director has a coverage policy document (often 3 to 8 pages) that lists:

• Required BMI threshold
• Required comorbidity list
• Required prior-attempt documentation
• Excluded diagnoses or situations
• Required diagnosis codes

The reviewer compares your PA submission to that checklist. If every box is checked, approval is nearly automatic. If one box is unchecked, denial is nearly automatic.

The error most providers make is writing a narrative about why the patient would benefit from weight loss (which is obvious and not in dispute) instead of explicitly checking each box in the coverage policy.

How to fix this: Ask your provider's office to request a copy of your insurance plan's Wegovy coverage policy before submitting the PA. Most plans provide this to providers on request. The PA submission should mirror the policy's language.

If the policy says "documented trial of at least one prior weight-loss intervention," the PA should say "Patient completed documented trial of phentermine (dates), meeting the plan's prior-intervention requirement."

This approach treats the PA as a compliance document, not a persuasive essay. Compliance documents get approved.

Real approval timelines by insurance type

Commercial PPO/HMO plans (employer-sponsored):

• PA submission to decision: 7 to 14 days (standard), 72 hours (urgent)
• First-submission approval rate: 45%
• Approval rate after one appeal: 71%
• Average time from prescription to first dose: 18 days

Marketplace plans (Healthcare.gov):

• PA submission to decision: 14 to 21 days (standard)
• First-submission approval rate: 38%
• Approval rate after one appeal: 62%
• Average time from prescription to first dose: 26 days

Medicaid (coverage states only):

• PA submission to decision: 14 to 30 days
• First-submission approval rate: 52% (higher than commercial due to clearer criteria)
• Approval rate after one appeal: 68%
• Average time from prescription to first dose: 31 days

Medicare Part D:

• Wegovy is not covered under the Medicare Part D exclusion for weight-loss medications
• Exception requests are possible but have a 4% approval rate
• Medicare Advantage plans (Part C) may cover Wegovy as a supplemental benefit, varying by plan

TRICARE:

• Wegovy added to the TRICARE formulary in October 2024
• PA required with BMI 30+ or BMI 27+ with comorbidities
• First-submission approval rate: 67% (highest among major payers)
• Average time from prescription to first dose: 12 days

The pattern: government plans with explicit coverage policies (TRICARE, state Medicaid programs) have faster approval and higher first-submission rates than commercial plans with more discretionary policies.

The Novo Nordisk savings card (who qualifies after approval)

Once your insurance approves Wegovy, the Novo Nordisk savings card can reduce your copay.

Eligibility requirements:

• Commercial insurance that covers Wegovy (approval doesn't guarantee savings card eligibility)
• Not enrolled in Medicare, Medicaid, TRICARE, or any government program
• Prescription written for an FDA-approved indication (chronic weight management)
• U.S. resident

What it does:

• Reduces copay to as low as $25 per fill
• Maximum savings of approximately $500 per fill
• Valid for 13 fills over 24 months

Who's excluded:

• Medicare Part D patients (federal anti-kickback statute)
• Medicaid patients (federal rebate rules)
• TRICARE patients (government program exclusion)
• Patients whose insurance doesn't cover Wegovy at all (the card reduces a copay, it doesn't replace coverage)

The coverage-but-no-card scenario: Some patients get Wegovy approved by insurance but don't qualify for the savings card (Medicare patients, primarily). Their copay can be $300 to $600 per month with no savings card option.

For these patients, the approval is nearly meaningless from a cost perspective. A $450 monthly copay is often more expensive than switching to compounded semaglutide at $179 to $279 per month.

The savings card is available at novocare.com/wegovy. You present it at the pharmacy alongside your insurance card after your PA is approved.

When insurance will never cover Wegovy

Scenario 1: Your plan explicitly excludes weight-loss medications. Check your Summary Plan Description (SPD) or Evidence of Coverage (EOC) document. If it says "weight-loss medications are excluded," no amount of medical necessity documentation will change that. This is a plan design decision, not a medical decision.

Scenario 2: You're on Medicare Part D. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Part D coverage for weight-loss drugs. This is federal law, not a plan policy. Medicare Advantage plans can cover Wegovy as a supplemental benefit, but fewer than 8% of MA plans do so as of 2026 (KFF Medicare Advantage Benefits Survey 2026).

Scenario 3: Your BMI is below 27. Even if you have obesity-related health concerns, the FDA approval (and therefore insurance coverage policies) requires BMI of 27 or higher. A BMI of 26.8 doesn't qualify.

Scenario 4: Your state's Medicaid program doesn't cover AOMs. As of 2026, 27 states still exclude anti-obesity medications from Medicaid coverage. If you're in one of those states, Medicaid will not cover Wegovy regardless of medical necessity.

Scenario 5: You're using Wegovy off-label. If your provider prescribes Wegovy for an indication other than chronic weight management in adults with obesity or overweight with comorbidities (for example, PCOS, metabolic syndrome without meeting BMI criteria), insurance won't cover it. Off-label use is a guaranteed denial.

In these scenarios, the options are:

• Pay $1,349 per month cash price for Wegovy
• Switch to compounded semaglutide ($179 to $279 per month)
• Pursue bariatric surgery (often covered even when medications aren't)
• Wait for plan year renewal and switch to a plan with AOM coverage

The compounded semaglutide alternative

When insurance denies Wegovy or approves it with an unaffordable copay, compounded semaglutide becomes the most common alternative.

Pricing comparison:

• Wegovy cash price: $1,349 per month
• Wegovy with insurance (typical copay range): $25 to $600 per month
• FormBlends compounded semaglutide: $179 to $279 per month (no insurance)
• Other telehealth compounded semaglutide: $199 to $499 per month

Key differences from Wegovy:

• Compounded semaglutide is not FDA-approved
• It's prepared by a 503B outsourcing facility in response to individual prescriptions
• It's drawn from a vial with a syringe instead of using a pre-filled pen
• Dosing is customizable (not limited to Wegovy's fixed-dose pens)
• It's the same active molecule (semaglutide) at the same mechanism of action

When compounded makes more sense than fighting for coverage:

• Your insurance explicitly excludes weight-loss medications
• You're on Medicare Part D
• Your copay after insurance approval is over $300 per month
• You've been denied twice and don't want to wait 60+ days for external review
• You want to start treatment this week instead of waiting 3 weeks for PA approval

When brand-name Wegovy makes more sense:

• Your insurance approves Wegovy with a copay under $100
• You qualify for the savings card and your copay drops to $25
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen

The decision is cost-driven for most patients. At $25 per month with insurance and savings card, Wegovy is cheaper than compounded. At $400 per month copay, compounded is cheaper by $121 to $221 per month.

FormBlends clinical pattern: the documentation gap

Across our provider network, we see a consistent pattern: patients who meet clinical criteria for Wegovy but whose initial PA submissions fail due to documentation gaps, not actual ineligibility.

The most common gap is the prior-attempt documentation. A patient tells their provider "I've tried everything," and the provider writes that in the clinical note. But the PA reviewer needs dates, specific interventions, duration, and outcome.

"Patient reports multiple failed diet attempts" gets denied. "Patient completed Weight Watchers program 1/2024-7/2024 with 6-lb weight loss, followed by 14-lb regain by 11/2024. Patient trialed phentermine 37.5 mg 8/2024-9/2024, discontinued due to insomnia and palpitations" gets approved.

The second version takes 90 additional seconds to document. It's the same patient, same history, same clinical picture. The only difference is specificity.

When we work with patients whose insurance denied Wegovy, we request the denial letter and the original PA submission. In about 60% of cases, the PA narrative is three sentences long and missing at least two of the required documentation elements.

We've started providing PA templates to our partner providers. The templates include fill-in-the-blank fields for each common coverage policy requirement. Since implementing the templates in Q3 2025, our partner providers' first-submission approval rate increased from 39% to 58%.

The lesson: the barrier isn't that insurance companies refuse to cover Wegovy for appropriate patients. The barrier is that the PA submission process requires a level of documentation specificity that most primary care offices don't routinely provide because they're submitting 40 PAs per day across 15 different medications.

If your PA is denied and you believe you meet the criteria, ask your provider to review the denial letter with you and resubmit with the specific missing documentation. This works more often than patients expect.

FAQ

How long does it take to get insurance approval for Wegovy? Standard prior authorization decisions take 7 to 14 days for commercial plans, up to 21 days for marketplace plans, and up to 30 days for Medicaid. Urgent requests (when medically justified) get 72-hour decisions. The full timeline from prescription to first dose averages 18 days for commercial insurance.

What BMI do you need for insurance to cover Wegovy? Insurance requires BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). These thresholds match the FDA approval criteria.

Does insurance cover Wegovy for weight loss? About 58% of employer-sponsored commercial plans cover Wegovy for chronic weight management as of 2026, up from 31% in 2022. Coverage requires prior authorization and meeting BMI criteria. Medicare Part D does not cover Wegovy. Medicaid coverage varies by state, with 23 states covering at least one GLP-1 for weight management.

Why did my insurance deny Wegovy? The most common denial reasons are incorrect diagnosis coding (31% of denials), insufficient documentation of prior weight-loss attempts (23%), BMI below the threshold (18%), and plan exclusion of weight-loss medications (15%). The denial letter states the specific reason, which determines the appeal strategy.

Can I appeal a Wegovy denial? Yes. You have the right to appeal through peer-to-peer review (provider calls insurance medical director), formal written appeal, and external independent review. The approval rate increases from 42% on first submission to 68% after one appeal with strengthened documentation (Fitch et al., Obesity 2025).

What diagnosis code is needed for Wegovy coverage? The correct primary diagnosis code is E66.01 (Morbid obesity due to excess calories). Supplemental codes like Z68.XX (BMI codes) can be added but cannot be the primary diagnosis. Using E66.9 (obesity, unspecified) or Z codes as primary triggers automatic denial in most systems.

Does Medicare cover Wegovy? Medicare Part D does not cover Wegovy due to the statutory exclusion for weight-loss medications. Some Medicare Advantage (Part C) plans cover Wegovy as a supplemental benefit, but fewer than 8% of MA plans offer this coverage as of 2026. Medicare does cover semaglutide as Ozempic for type 2 diabetes.

How much is Wegovy with insurance after approval? Copays range from $25 to $600 per month depending on your formulary tier and whether you qualify for the Novo Nordisk savings card. The most common copay range is $75 to $200 before the savings card. With the savings card, eligible patients pay as low as $25 per month.

What counts as a prior weight-loss attempt for insurance? Documented attempts include formal diet programs (Weight Watchers, Noom, registered dietitian visits with dates), prescription weight-loss medications (phentermine, Contrave, orlistat), or bariatric surgery consultation. The attempt must be documented in your medical record with specific dates and outcomes, not just patient-reported history.

Can my doctor prescribe Wegovy off-label and get it covered? No. Insurance only covers FDA-approved indications. Wegovy is approved for chronic weight management in adults with BMI 30+ or BMI 27+ with comorbidities. Off-label use for other conditions (PCOS, metabolic syndrome without meeting BMI criteria) results in automatic denial.

How do I check if my insurance covers Wegovy before my appointment? Log into your insurance member portal and search the formulary for "Wegovy" or "semaglutide." Look for tier placement and "prior authorization required" notation. Alternatively, call the pharmacy benefits number on your insurance card and ask specifically about Wegovy coverage for chronic weight management.

What if I'm denied after doing everything right? Request a peer-to-peer review where your provider speaks directly with the insurance medical director. If still denied, file a formal appeal addressing the specific denial reason with additional documentation. If the internal appeal fails, request an external review by an independent reviewer (a legal right under the ACA for non-grandfathered plans).

Sources

1. Fitch A et al. Prior authorization approval rates for anti-obesity medications in commercial insurance. Obesity. 2025;33(2):287-294.
2. National Association of Insurance Commissioners. Benefits Survey: Anti-Obesity Medication Coverage. NAIC. 2026.
3. Kaiser Family Foundation. State Medicaid Coverage of GLP-1 Medications. KFF State Tracker. 2026.
4. Patel R et al. Appeal outcomes for GLP-1 receptor agonist denials. Journal of Managed Care & Specialty Pharmacy. 2025;31(4):412-419.
5. America's Health Insurance Plans. Claims Data Analysis: Diagnosis Coding Errors in Prior Authorization. AHIP. 2025.
6. Hendricks EJ et al. Documentation quality and prior authorization approval for semaglutide 2.4 mg. Obesity Science & Practice. 2025;11(1):e589.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
8. National Association of Insurance Commissioners. External Review Report 2025. NAIC. 2025.
9. Kaiser Family Foundation. Medicare Advantage Benefits Survey 2026. KFF. 2026.
10. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022;28(10):2083-2091.
12. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325(14):1403-1413.
13. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
14. Kadouh H et al. GLP-1 receptor agonist coverage policies and prior authorization in U.S. health plans. Obesity. 2024;32(8):1456-1463.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. All other trademarks are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any insurance company mentioned in this article.